EGFR-T790M mutation associated with acquired resistance to first-generation EGFR tyrosine kinase inhibitors in Vietnamese Non-Small-Cell Lung Cancer patients: EGFR-T790M mutation with acquired resistance to first-generation EGFR tyrosine kinase inhibitors in non-small cell lung cancer

Le Hoan; Ngoc Cuong Nguyen; Tran Khanh Chi; Tran Huy Thinh; Tran Van Khanh; Thieu Thi Tra My

doi:10.15625/2525-2518/18061

Author affiliations

Authors

Le Hoan Respiratory Medicine Department, Hanoi Medical University Hospital, 1 Ton That Tung, Dong Da, Ha Noi, Viet Nam https://orcid.org/0000-0002-3514-7235
Ngoc Cuong Nguyen Diagnostic Imaging and Interventional Radiology Center, Hanoi Medical University Hospital, 1 Ton That Tung, Dong Da, Ha Noi, Viet Nam https://orcid.org/0000-0001-8809-9583
Tran Khanh Chi Biochemistry Department, Hanoi Medical University, 1 Ton That Tung, Dong Da, Ha Noi, Viet Nam https://orcid.org/0009-0000-9859-2822
Tran Huy Thinh Biochemistry Department, Hanoi Medical University, 1 Ton That Tung, Dong Da, Ha Noi, Viet Nam
Tran Van Khanh Center for Gene and Protein Research, Hanoi Medical University, 1 Ton That Tung, Dong Da, Ha Noi, Viet Nam
Thieu Thi Tra My Diagnostic Imaging and Interventional Radiology Center, Hanoi Medical University Hospital, 1 Ton That Tung, Dong Da, Ha Noi, Viet Nam

DOI:

https://doi.org/10.15625/2525-2518/18061

Keywords:

EGFR-T790M mutation, acquired resistance EGFR-TKIs, targeted therapy, NSCLC

Abstract

Background: non-small cell lung cancer (NSCLC) patients who had epidermal growth factor receptor (EGFR) mutations sensitive to EGFR tyrosine kinase inhibitors (TKIs) had a high response rate to target therapies. Epidermal growth factor receptor (EGFR) T790M mutation is the most common mechanism of acquired resistance to first-generation EGFR TKIs. Objective: The aim of this study was to analyze the incidence of EGFR T790 mutation, the progression-free survival (PFS) in the patients who progress on the first‑ generation EGFR‑TKIs. This study also investigates the correlation between T790M mutation and clinical, subclinical features, progression-free survival of NSCLC Vietnamese patients.

Patients and methods: We analyzed 66 NSCLC patients who had acquired resistance to first-generation EGFR-TKIs. The clinical data, PFS and the mechanism of acquired resistance were obtained. The Kaplan-Meier method and the log-rank test were used to analyze the PFS and compare between subgroups of patient characteristics. The correlations between the patient’s characteristics and EGFR-T790M mutation status were analyzed by Chi-square and Fisher’s exact tests.

Results: At the progressive period, EGFR T790M mutation was detected in 54.5% of patients. The median PFS were 14.48 ± 3.9 months (range: 8- 26 months). Patients who were older than 60 years old or had comorbidities had significantly shorter PFS than the subgroups without (P≤0.05). The age, gender, smoking status, comorbidities, pathological features were not significantly correlated with the development of EGFR-T790M (P > 0.05). The average PFS was not significantly different between the EGFR-T790M group and the non-EGFR-T790M group (P=0.642).

Conclusion: In our cohort study, more than half of all patients had T790M mutation after being treated with first-generation EGFR TKIs. Age and comorbidities were associated with PFS but the EGFR-T790M mutation was not correlated with PFS.

Downloads

Download data is not yet available.

References

1. Hyuna S., Jacques F., Rebecca L., Mathieu L., Isabelle S., Ahmedin J. and Freddie B. - Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J. Clin. 71 (3) (2021) 209-249. doi:10.3322/caac.21660

2. Umair M, Rami M, Yujie Z and Yanyan L. - Targeted therapy in advanced non-small cell lung cancer: current advances and future trends, J. Hematol OncolJ Hematol Oncol. 14 (1) (2021) 108. doi:10.1186/s13045-021-01121-2

3. Xiaojuan A., Xialing G., Jun W., Andreea L., Patrick M., Dianzheng Z. and Shudong Z. - Targeted therapies for advanced non-small cell lung cancer, Oncotarget 9 (101) (2018) 37589-37607. doi:10.18632/oncotarget.26428

4. D’Cunha J. and Antonoff M. - Non-small cell lung cancer: the era of targeted therapy, Lung Cancer Targets Therapy, Published online July 31 (2012) 31-41. doi:10.2147/LCTT.S16442

5. Chan B. A and Hughes B. G. M. - Targeted therapy for non-small cell lung cancer: current standards and the promise of the future, Transl Lung Cancer Res. 4 (1) (2015) 36-54. doi:10.3978/j.issn.2218-6751.2014.05.01

6. Kim C. and Liu S. V. - First-line EGFR TKI therapy in non-small-cell lung cancer: looking back before leaping forward, Ann Oncol Off J. Eur. Soc. Med. Oncol. 30 (12) (2019) 1852-1855. doi:10.1093/annonc/mdz415

7. Geoffrey R., Maria E., Camelia S., Gregory J., Juliann C., Mark G., William P., Marc L. and Vincent A. - Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation, Clin Cancer Res. 17 (6) (2011) 1616-1622. doi:10.1158/1078-0432.CCR-10-2692

8. Wu S. G. and Shih J. Y. - Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer, Mol Cancer. 17 (1) (2018) 38. doi:10.1186/s12943-018-0777-1

9. Nagano T., Tachihara M., and Nishimura Y. - Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy, Cells 7 (11) (2018) E212. doi:10.3390/cells7110212

10. David J., William P., Gregory J., Jeffrey A., Mark G., Pasi A., Thomas L., Bruce E. and Vincent A. - Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer, J. Clin Oncol. 28 (2) (2010) 357-360. doi:10.1200/JCO.2009.24.7049

11. LawrenceH., Saskia L., ElisabethV., Robert F., Stephen G., Sumithra M., Lalitha S., Jan B., Alice C., Janet D., Wendy H., Otto S., Erich P., Nancy L., Yan L., Patrick T., Jedd D., and Lesley S. - RECIST 1.1 - Update and clarification: From the RECIST committee. Eur. J. Cancer. 62 (2016) 132-137. doi:10.1016/j.ejca.2016.03.081

12. Kuiper J. L., Heideman D. A., Thunnissen E., Paul M. A., van Wijk A. W., Postmus P. E., and Smit E. F. - Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients, Lung Cancer Amst Neth. 85 (1) (2014) 19-24. doi:10.1016/j.lungcan. 2014.03.016.

13. Wang Z. F., Ren S. X., Li W., and Gao G. H. - Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis, BMC Cancer 18 (1) (2018) 148. doi:10.1186/s12885-018-4075-5

14. Jaiswal R., Pinninti R.,Mohan K., Santa A., Pavan K., Nambaru L., Murthy S., Veeriah K., and Rajappa S. - T790M mutation and clinical outcomes with osimertinib in patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer, Indian J. Med. Paediatr Oncol 40 (01) (2019) 73-78. doi:10.4103/ijmpo.ijmpo_215_18

15. Nguyen K. S. H., Kobayashi S., and Costa D. B. - Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway, Clin Lung Cancer 10 (4) (2009) 281-289. doi:10.3816/CLC.2009.n.039

16. Cardona A. F., Arrieta O., Zapata M. I., Rojas L., Wills B., Reguart N., Karachaliou N., Carranza H., Vargas C., Otero J., Archila P., Martín C., Corrales L., Cuello M., Ortiz C., Pino L. E., Rosell R., and Zatarain-Barrón Z. L. - Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP), Target Oncol. 12 (4) (2017) 513-523. doi:10.1007/s11523-017-0497-2

17. Chantharasamee J., Poungvarin N., Danchaivijitr P., and Techawatanawanna S. - Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation, BMC Cancer 19 (1) (2019) 701. doi:10.1186/s12885-019-5913-9.

18. Qiuyi Z., Ee K., Feiyu N., Wei D., Zhihong C., Chongrui X., Xuchao Z., Ning Z., Jian S., Jinji Y., Honghong Y., Yilong W., and Qing Z. - The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma, Oncotarget 8 (3) (2017) 4994-5002. doi:10.18632/oncotarget.14007

19. Li W., Ren S., Li J., Li A., Fan L., Li X., Zhao C., He Y., Gao G., Chen X., Li S., Shi J., Zhou C., Fei K., and Schmid-Bindert G. - T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients, Lung Cancer Amst Neth. 84 (3) (2014) 295-300. doi:10.1016/j.lungcan.2014.03.011

Kim H. R., Lee J. C., Kim Y. C., Kim K. S., Oh I. J., Lee S. Y., Jang T. W., Lee M. K., Shin K. C., Lee G. H., Ryu J. S., Jang S. H., Son J. W., Lee J. E., Kim S. Y., Kim H. J., and Lee K. Y. - Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment, Lung Cancer Amst Neth. 83 (2) (2014) 252-258. doi:10.1016/j.lungcan. 2013.11.008

20. Qinghua X., Hui L., Shuyan M., Tao J., Xuefei L., Shixiong L., Shengxiang R., and Caicun Z. - First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease, J. Cancer 10 (2) (2019) 522-529. doi:10.7150/jca.26494

21. Wang Y., Wei Y., Ma X., Ma X., and Gong P. - Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study, Medicine (Baltimore) 97 (28) (2018) e11346. doi:10.1097/MD.0000000000011346.